This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| QUADAS | |
|---|---|
| Name | QUADAS |
| Purpose | Quality assessment of diagnostic accuracy studies |
| First published | 2003 |
| Developed by | University of Bristol; Cochrane Collaboration (influential contributors) |
| Latest version | QUADAS-2 (2011) |
| Domains | Patient selection; Index test; Reference standard; Flow and timing |
| Type | Critical appraisal tool |
QUADAS
QUADAS is a validated tool used to assess the methodological quality of primary studies of diagnostic accuracy. It provides structured domains and signaling questions to evaluate risk of bias and applicability in studies that compare index tests to reference standards. QUADAS has been influential across evidence synthesis activities by organizations and institutions conducting diagnostic systematic reviews and guideline development.
QUADAS was developed amid growing recognition by entities such as the Cochrane Collaboration, the World Health Organization, the National Institute for Health and Care Excellence, and the U.S. Preventive Services Task Force that diagnostic accuracy evidence required standardized appraisal. Early impetus drew on methodological work from researchers at the University of Bristol, the University of Oxford, and the McMaster University group associated with the Canadian Task Force on Preventive Health Care. QUADAS sought to harmonize approaches used by review groups affiliated with the Cochrane Screening and Diagnostic Tests Methods Group, the Agency for Healthcare Research and Quality, and national health technology assessment bodies such as the National Institute for Health Research.
The original QUADAS instrument emerged from a collaboration among methodologists, clinicians, and statisticians with contributions from teams linked to Imperial College London, the University of Glasgow, and the Karolinska Institutet. The initial publication prompted revisions leading to QUADAS-2, published in 2011 after consultation with groups including the Cochrane Collaboration and the International Society for Pharmacoeconomics and Outcomes Research. QUADAS-2 shifted from a checklist to a domain-based bias and applicability framework similar to tools used in contexts such as the GRADE Working Group and the CONSORT recommendations. Subsequent guidance and extensions have been referenced by professional societies like the European Society of Cardiology, the American College of Physicians, and the Radiological Society of North America.
QUADAS-2 comprises four domains: Patient Selection, Index Test, Reference Standard, and Flow and Timing. Each domain contains signaling questions to judge risk of bias and concerns regarding applicability. The Patient Selection domain interrogates sampling methods and exclusions with parallels to considerations addressed by the STARD initiative and the TRIPOD statement. The Index Test domain examines blinding and pre-specification similar to standards promoted by the International Committee of Medical Journal Editors and the British Medical Journal editorial policies. The Reference Standard domain assesses whether the comparator accurately classifies the target condition, an issue central to debates involving institutions such as the Food and Drug Administration and the European Medicines Agency. The Flow and Timing domain evaluates attrition and the interval between tests, echoing principles from the New England Journal of Medicine and trialists associated with the MRC Clinical Trials Unit.
QUADAS-2 avoids numeric summative scores; instead, reviewers make domain-specific risk judgments. This approach parallels developments in tools like the Risk Of Bias (RoB) tool for randomized trials and aligns with appraisal concepts used by the U.S. Department of Veterans Affairs evidence programs.
QUADAS and QUADAS-2 are widely used by systematic review teams at entities such as the Cochrane Collaboration, the World Health Organization, Health Technology Assessment agencies like the Netherlands National Health Care Institute, and the Canadian Agency for Drugs and Technologies in Health. Reviewers apply QUADAS-2 when synthesizing diagnostic accuracy measures including sensitivity, specificity, likelihood ratios, and area under the receiver operating characteristic curve—metrics frequently discussed in literature from the American Statistical Association and the Royal Statistical Society. QUADAS-2 outputs inform subgroup analyses, meta-regression, and GRADE assessments performed by guideline panels from organizations such as the World Heart Federation and the American Thoracic Society.
Empirical evaluations by teams at institutions including the University of Oxford, the University of Toronto, and the London School of Hygiene & Tropical Medicine have examined inter-rater reliability and construct validity of QUADAS instruments. Strengths include structured domain focus and adaptability; criticisms include variability in reviewer application, potential subjectivity in signaling question interpretation, and challenges in mapping risk judgments to quantitative synthesis. Commentators from journals such as The Lancet, the BMJ, and Annals of Internal Medicine have debated the absence of an overall numeric quality score and the need for clearer training materials—points echoed by guideline developers at the National Health Service and academic groups affiliated with the Johns Hopkins University.
Guidance for implementing QUADAS-2 is provided through training resources produced by the Cochrane Collaboration, the Equator Network, and methodologists from the University of Bern and the University of Melbourne. Reporting recommendations encourage integration with reporting standards like STARD and transparency practices promoted by the Open Science Framework and publishers including PLOS Medicine. Systematic reviewers are advised to present domain-level risk of bias tables and to document judgments and rationales, practices adopted by review groups at the National Institute for Health and Care Excellence and the Agency for Healthcare Research and Quality.
Category:Diagnostic accuracy